CytomX Therapeutics (CTMX) EBIAT (2016 - 2025)
Historic EBIAT for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' EBIAT fell 34806.49% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10258.86%. This contributed to the annual value of $31.9 million for FY2024, which is 570087.87% up from last year.
- As of Q3 2025, CytomX Therapeutics' EBIAT stood at -$14.2 million, which was down 34806.49% from -$154000.0 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' EBIAT ranged from a high of $23.5 million in Q1 2025 and a low of -$34.8 million during Q4 2021
- For the 5-year period, CytomX Therapeutics' EBIAT averaged around -$9.2 million, with its median value being -$6.5 million (2024).
- Data for CytomX Therapeutics' EBIAT shows a peak YoY increase of 215519.71% (in 2024) and a maximum YoY decrease of 50110.4% (in 2024) over the last 5 years.
- Quarter analysis of 5 years shows CytomX Therapeutics' EBIAT stood at -$34.8 million in 2021, then skyrocketed by 74.8% to -$8.8 million in 2022, then skyrocketed by 109.54% to $837000.0 in 2023, then soared by 2155.2% to $18.9 million in 2024, then plummeted by 175.38% to -$14.2 million in 2025.
- Its EBIAT stands at -$14.2 million for Q3 2025, versus -$154000.0 for Q2 2025 and $23.5 million for Q1 2025.